Onyx Pharma - gehts jetzt los? - 500 Beiträge pro Seite

[stormman]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[mitie]

Hallo!
Ich schätze einfach mal, die Konsolidierung ist ausgestanden und es geht jetzt mit Riesenschritten auf das ausgesprochene Kursziel los (hoffe ich zumindest). Hab selbst bei 11,9 Euro gekauft, halte das KZ von 100 Dollar allerdings für zu hoch gegriffen.
Mike

[das276]

Onyx Pharmaceuticals Receives Research
Milestone on Development

of Armed
Anticancer Virus



RICHMOND, Calif., May 23 /PRNewswire/ --
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has
received
from its corporate partner, Warner-Lambert Company (NYSE: WLA), a
research
milestone payment of $3.7 million. In addition to the lead product, ONYX-015,
the two companies are collaborating on the development of two therapeutic
viruses armed with anticancer genes.

Onyx received the milestone payment for demonstrating the scientific
feasibility of using a selectively replicating adenovirus to deliver an

anticancer gene. "This payment marks significant progress toward the
development of the first of two armed virus therapeutics with enhanced
anticancer properties that we are developing with Warner-Lambert," said

Hollings Renton, President and Chief Executive Officer of Onyx
Pharmaceuticals. "The armed virus products are based on a genetically
modified
adenovirus that selectively targets and replicates in precancerous and
cancerous cells with abnormal p53 function. The virus is armed with anticancer

therapeutic genes. The significant features of this technology are selective
expression and amplification of the anticancer genes within the local tumor

environment. Because the virus replicates, it steadily increases the
concentration of the anticancer therapeutic agent in the cancer mass, which

adds to the virus` anticancer effects."

Onyx and Warner-Lambert will jointly develop the two armed virus products.
For products commercialized from the collaboration, Onyx and
Warner-Lambert
will co-promote in the United States and Canada and share equally the
resulting profits or losses from such product sales. Warner-Lambert holds the
right to commercialize the viral therapeutics in the rest of the world, with
the obligation to pay Onyx a royalty based on net sales in those markets.
Additionally, Warner-Lambert is providing financial support for the research
and development of the two armed therapeutic viruses. Onyx will co-fund
25% of the expenses of the products once selected for clinical development.

Onyx Pharmaceuticals is engaged in the discovery, development and
commercialization of novel cancer therapies based on the genetic mutations
that cause the disease. The company has a proprietary virus technology
platform that relies on selectively killing cancer cells based on the presence
of mutations in specific tumor suppressor genes in these cells. The company
pursues a strategy of establishing corporate partnerships that provide
complementary technologies to enhance its platform as well as skills in drug
development, manufacturing, and marketing and sales. The Onyx Web site
address
is www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding
the development of potential human therapeutic products that involve a number

of risks and uncertainties. Actual events may differ from the company`s
expectations. In addition to the matters described in this press release, the
timeline for clinical activity, results of pending or future clinical trials,
including the trials of ONYX-015, and changes in the status of the company`s
collaborative relationships, as well as the risk factors listed from time to
time in the company`s periodic reports filed with the Securities and Exchange
Commission, including but not limited to its Annual Report on Form 10-K, may

affect the actual results achieved by the company.

SOURCE Onyx Pharmaceuticals Inc.

-0- 05/23/2000
/CONTACT: Helen S. Kim of Onyx Pharmaceuticals, Inc., 510-262-8737/
/Web site: http://www.onyx-pharm.com/


(ONXX WLA)

CO: Onyx Pharmaceuticals Inc.; Warner-Lambert Company
ST: California
IN: MTC BIO
SU:

[chartmike]

Hallo, bin selbst in onxx drin und sehe leider für kurze zeit kurse um die 7-8$ da otxx vom chart nach unten gedreht hat.
Mit nachkaufen warten bis der MACD wieder im Daily Chart ein kauf Signal gibt.
Chartmike

[das276]

Onyx says agent may act against variety of tumors

RICHMOND, Calif., May 24 (Reuters) - Onyx Pharmaceuticals
Inc. , which specializes in new cancer therapies, on
Wednesday said that its CI-1042 (ONYX-015) may act against a
variety of tumors, such as head and neck tumors, as well as
colorectal, pancreatic and ovarian cancer.
CI-1042 is a tumor-selective therapy that self-amplifies
in the presence of tumor tissue.
The company said in a statement in its annual meeting of
the American Society of Clinical Oncology that results from
clinical studies on CI-1042 (ONYX-015) showed that the drug may
be useful on a variety of tumor types and in a wide variety of
cancers with mutations within the p53-tumor suppressor pathway.

Also, results from these studies showed that administration
of the drug is not limited to direct intratumoral injection,
but may also be safely administered in other ways in exploring
and treating colorectal and pancreatic cancer.
Shares of Onyx, which is conducting earlier stage clinical
studies of CI-1042 in a variety of other cancer and precancer
indications with partner Warner-Lambert , closed at
9-1/2 on the Nasdaq exchange on Tuesday.
((Lee Daniels, New York Equities Desk, 212-859-1619))

[das276]

Hi zusammen,

Ich habe vor kurzem im Fernsehen eine Analyse über den Zusammenhang des p53-Gens mit
der Krebsentstehung gesehen.

Wenn es ONYX gelingen sollte, auf diesem Gebiet brauchbare Resultate zu erzielen,
so könnte ich mir durchaus irgendwann dreistellige Kurse vorstellen.

Man beachte den letzten Absatz im vorstehenden Artikel, der darauf verweist,
dass das Mittel CI-1042 eine breite Anwendungsmöglichkeit in
der Behandlung verschiedener Krebsarten erwarten läßt.

Bis später.
das276